Want to see IRMD full AI Analyst Report?
IRMD Stock Chart & Stats
$94.49
$0.59(0.62%)
At close: 4:00 PM EDT
$94.49
$0.59(0.62%)
Day’s Range― - ―
52-Week Range$67.84 - $107.90
Previous Close$95.08
Volume67.19K
Average Volume (3M)128.61K
Market Cap
$1.11B
Enterprise Value$1.17K
Total Cash (Recent Filing)$59.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)47.9
Beta0.62
Next Earnings
Oct 29, 2026EPS Estimate
0.55Next Dividend Ex-DateN/A
Dividend Yield1.45%
Share Statistics
EPS (TTM)1.82
Shares Outstanding12,786,991
10 Day Avg. Volume112,129
30 Day Avg. Volume128,611
Financial Highlights & Ratios
PEG Ratio3.34
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$120.00Price Target Upside27.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.08
Revenue Forecast (FY)$91.20M
Bulls Say, Bears Say
Bulls Say
High Margins And Durable ProfitabilityIRMD’s high gross and net margins indicate differentiated medical-device economics and pricing power. Sustained profitability provides internal funding for product development, manufacturing expansion and commercial growth without relying heavily on external capital.
Debt-free Balance Sheet And Strong Cash GenerationMinimal leverage materially reduces financial risk and interest burden, while strong operating and free cash flow support resilience, investment and shareholder returns. This balance-sheet flexibility is especially valuable during product ramps or hospital spending cycles.
3870 Adoption And Recurring Revenue ExpansionStrong 3870 bookings suggest customer acceptance and a growing backlog, while higher-value quad systems can lift order economics. Growing disposables and services deepen recurring revenue from the installed base, improving revenue quality over time.
Bears Say
Moderating Revenue Growth And Weak Quarterly MomentumSlower top-line growth indicates that recent profitability has not yet translated into sustained revenue acceleration. Continued moderation could constrain operating leverage and make results more dependent on successful 3870 adoption and replacement demand.
Production Ramp Execution And Margin RiskScaling 3870 production rapidly may keep labor, overhead and inefficiency costs elevated before manufacturing reaches historic productivity. If the ramp misses targets, gross-margin recovery and full-year earnings guidance could face pressure.
3860 Phase-out Creates Transition And Service RiskReplacing the legacy 3860 platform can create timing and supply-chain friction across equipment, service and disposables. Longer lead times or reduced support for the legacy installed base could delay revenue recognition and complicate customer conversions.
Iradimed News
IRMD FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was $67.84 and its highest was $107.90 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is $1.11B.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Oct 29, 2026 which is in 63 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on Jul 31, 2026. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Undervalued.
Does Iradimed Corp pay dividends?
Iradimed Corp pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 1.45%. See more information on Iradimed Corp dividends here
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.55.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,786,991 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of $0.46 in its last earnings report, beating expectations of $0.44. Following the earnings report the stock price went down -4.569%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in IRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$120.00 (27.00% Upside)
$120.00 (27.00% Upside)
Blogger Sentiment
Bearish
IRMD Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 11.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $285.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.3%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.27%
12-Months-Change
Fundamentals
Return on Equity
1.45%
Trailing 12-Months
Asset Growth
8.01%
Trailing 12-Months
Company Description
Iradimed Corp
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
IRMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by a successful product launch (3870 pump), strong bookings (bookings >2x units shipped), higher ASPs from quad replacements, record monitor orders, and improving recurring revenue and cash flows. Near-term challenges include margin compression and higher costs from the initial production ramp, a modest decline in quarterly net income and gross margin, and an elevated effective tax rate. Management provided clear plans and guidance to double down on ramp execution, expects significant cost reductions in Q3 and near-historic efficiencies by Q4, and reaffirmed full-year guidance — resulting in confidence that the positive drivers outweigh the near-term operational headwinds.View all IRMD earnings summariesIRMD Stock 12 Month Forecast
Average Price Target
$120.00
▲(27.00% Upside)
Technical Analysis
Ownership Overview
34.85% Insiders
12.95% Mutual Funds
17.35% Other Institutional Investors
24.95% Public Companies and
Individual Investors